Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis

Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis

Abstract Recent phase 3 randomized controlled trials (RCTs) demonstrate the promising impact of immune checkpoint inhibitor (ICI)-based combination therapies on locally advanced or metastatic urothelial carcinoma (UC). However, comparative data on the efficacy and toxicity of different ICI-based com...

Full description

Saved in:
Bibliographic Details
Main Authors: Takafumi Yanagisawa, Keiichiro Mori, Akihiro Matsukawa, Tatsushi Kawada, Satoshi Katayama, Ekaterina Laukhtina, Pawel Rajwa, Fahad Quhal, Benjamin Pradere, Wataru Fukuokaya, Kosuke Iwatani, Renate Pichler, Jeremy Yuen-Chun Teoh, Marco Moschini, Wojciech Krajewski, Jun Miki, Shahrokh F. Shariat, Takahiro Kimura, European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)
Format: Article
Language:English
Published: Springer 2025-02-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Chemotherapy
Enfortumab vedotin
Immune checkpoint inhibitors
Metastasis
Urothelial carcinoma
Online Access:https://doi.org/10.1007/s00262-024-03910-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-024-03910-3

Similar Items